CompareMarketResearchRequest a sample
Home / Healthcare / Bladder Cancer Array

Healthcare · Market report

Bladder Cancer Array Market Size, Share and Forecast 2026-2036

The global bladder cancer array market is worth USD 308 mn in 2026 and is forecast to reach USD 729 mn by 2036, growing at a 9.0% CAGR. United States is the largest country market and Methylation and mutation assays is the largest by test segment.

USD 308 mnMarket size 2026
USD 729 mnForecast 2036
9.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global bladder cancer array market is worth USD 308 mn in 2026 and is forecast to reach USD 729 mn by 2036, growing at a 9.0% CAGR. United States is the largest country market and Methylation and mutation assays is the largest by test segment.

ScopeNon-invasive urine and array-based tests used to detect and monitor bladder cancer, including FISH, methylation, mutation and protein marker tests and microarrays, run in laboratories.
IndustryHealthcare
Value 2025USD 280 mn
Value 2026USD 308 mn
Value 2036USD 729 mn
CAGR 2026-20369.0%
Volume 2026995 thousand tests
Volume 20362,477 thousand tests
Average price 2026USD 310 per test
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Bladder Cancer Array market size and forecast, 2026-2036

Exhibit 1The global bladder cancer array market is forecast to grow from USD 308 mn in 2026 to USD 729 mn by 2036, more than doublingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 9.0%
Bladder Cancer Array market value, 2025 to 2036Market value by year. 2025: USD 280 mn; 2026: USD 308 mn; 2027: USD 336 mn; 2028: USD 366 mn; 2029: USD 399 mn; 2030: USD 435 mn; 2031: USD 474 mn; 2032: USD 517 mn; 2033: USD 563 mn; 2034: USD 614 mn; 2035: USD 669 mn; 2036: USD 729 mn. Compound annual growth rate 2026 to 2036: 9.0%.2025308 mn2026474 mn2031729 mn20369.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 308 mn
2027USD 336 mn
2028USD 366 mn
2029USD 399 mn
2030USD 435 mn
2031USD 474 mn
2032USD 517 mn
2033USD 563 mn
2034USD 614 mn
2035USD 669 mn
2036USD 729 mn

Bladder Cancer Array market segmentation

By test

Exhibit 2Methylation and mutation assays is the largest segment by test, with 34.0% of 2026 revenueEstimated share of 2026 global revenue, by test
Bladder Cancer Array market share by test, 2026Share of 2026 revenue by test. Methylation and mutation assays: 34.0%; FISH tests: 26.0%; Protein marker tests: 22.0%; Microarray and sequencing panels: 18.0%.Methylation and mutation assays34.0%FISH tests26.0%Protein marker tests22.0%Microarray and sequencing panels18.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Methylation and mutation assays34.0%45.6%USD 105 mn12.2%
FISH tests26.0%16.7%USD 80 mn4.3%
Protein marker tests22.0%15.6%USD 68 mn5.3%
Microarray and sequencing panels18.0%22.1%USD 55 mn11.3%

By use

Exhibit 3Surveillance of known cancer adds the most revenue by use, growing from USD 166 mn in 2026 to USD 372 mn by 2036Estimated revenue in USD by use, 2026 and 2036 forecast
Bladder Cancer Array market by use, 2026 and 2036Revenue by use in 2026 and 2036. Surveillance of known cancer: USD 166 mn in 2026, USD 372 mn in 2036, change +124%; Haematuria evaluation: USD 99 mn in 2026, USD 231 mn in 2036, change +134%; Screening of high-risk groups: USD 43 mn in 2026, USD 126 mn in 2036, change +193%.20262036 forecastChangeSurveillance of known cancer+124%166 mn372 mnHaematuria evaluation+134%99 mn231 mnScreening of high-risk groups+193%43 mn126 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Surveillance of known cancer54.0%51.0%USD 166 mn8.4%
Haematuria evaluation32.0%31.6%USD 99 mn8.9%
Screening of high-risk groups14.0%17.3%USD 43 mn11.4%

By buyer

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Reference laboratories56.0%55.7%USD 172 mn8.9%
Hospital laboratories34.0%32.3%USD 105 mn8.4%
Urology clinics10.0%11.9%USD 31 mn10.9%

By array format

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Microarray52.0%46.0%USD 160 mn7.7%
Bead array24.0%26.0%USD 74 mn9.9%
Protein array12.0%14.0%USD 37 mn10.7%
Other formats12.0%14.0%USD 37 mn10.7%

By clinical question

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Diagnosis34.0%33.0%USD 105 mn8.7%
Recurrence monitoring38.0%37.0%USD 117 mn8.7%
Prognosis and risk16.0%17.0%USD 49 mn9.7%
Therapy selection12.0%13.0%USD 37 mn9.9%

Top 25 countries for bladder cancer array by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 92.0% of 2026 revenue and the 25 countries below together hold 98.1%.

Exhibit 4United States is the largest country market at USD 142 mn in 2026, and the three largest countries hold 61.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Bladder Cancer Array market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 142 mn, 46.0%; Germany: USD 25 mn, 8.0%; Japan: USD 22 mn, 7.0%; China: USD 22 mn, 7.0%; United Kingdom: USD 18 mn, 6.0%; France: USD 15 mn, 5.0%; Italy: USD 12 mn, 4.0%; Spain: USD 9.2 mn, 3.0%; Australia: USD 9.2 mn, 3.0%; South Korea: USD 9.2 mn, 3.0%.United States142 mn 46.0%Germany25 mn 8.0%Japan22 mn 7.0%China22 mn 7.0%United Kingdom18 mn 6.0%France15 mn 5.0%Italy12 mn 4.0%Spain9.2 mn 3.0%Australia9.2 mn 3.0%South Korea9.2 mn 3.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 142 mn46.0%USD 330 mn8.8%
2GermanyUSD 25 mn8.0%USD 55 mn8.3%
3JapanUSD 22 mn7.0%USD 48 mn8.4%
4ChinaUSD 22 mn7.0%USD 66 mn11.8%
5United KingdomUSD 18 mn6.0%USD 43 mn8.8%
6FranceUSD 15 mn5.0%USD 34 mn8.3%
7ItalyUSD 12 mn4.0%USD 28 mn8.4%
8SpainUSD 9.2 mn3.0%USD 22 mn9.0%
9AustraliaUSD 9.2 mn3.0%USD 23 mn9.4%
10South KoreaUSD 9.2 mn3.0%USD 25 mn10.4%
11NetherlandsUSD 2.5 mn0.8%USD 5.7 mn8.5%
12SwitzerlandUSD 2.4 mn0.8%USD 5.5 mn8.6%
13SwedenUSD 1.9 mn0.6%USD 4.5 mn8.7%
14BelgiumUSD 1.6 mn0.5%USD 3.7 mn8.6%
15BrazilUSD 1.6 mn0.5%USD 4.0 mn9.8%
16IndiaUSD 1.5 mn0.5%USD 3.9 mn9.8%
17PolandUSD 1.4 mn0.4%USD 3.5 mn9.9%
18AustriaUSD 1.2 mn0.4%USD 2.7 mn8.4%
19DenmarkUSD 1.1 mn0.3%USD 2.4 mn8.7%
20IsraelUSD 0.92 mn0.3%USD 2.1 mn8.6%
21TaiwanUSD 0.71 mn0.2%USD 1.8 mn9.5%
22MexicoUSD 0.55 mn0.2%USD 1.5 mn10.2%
23SingaporeUSD 0.49 mn0.2%USD 1.2 mn9.7%
24PortugalUSD 0.43 mn0.1%USD 1.0 mn9.0%
25TurkeyUSD 0.37 mn0.1%USD 0.95 mn9.9%
Rest of worldUSD 5.9 mn1.9%USD 12 mn7.7%
Exhibit 5United States and China account for 55% of the USD 421 mn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Bladder Cancer Array market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 308 mn. United States: +USD 188 mn; China: +USD 44 mn; Germany: +USD 30 mn; Japan: +USD 27 mn; United Kingdom: +USD 25 mn; 20 other countries: +USD 102 mn; Rest of world: +USD 6.5 mn. Market value 2036: USD 729 mn.Market value 2026308 mnUnited States+188 mnChina+44 mnGermany+30 mnJapan+27 mnUnited Kingdom+25 mn20 other countries+102 mnRest of world+6.5 mnMarket value 2036729 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Abbott
  • Pacific Edge
  • Qiagen
  • Exact Sciences

Group 2: Regional and specialist players

  • Nucleix
  • Convergent Genomics
  • Oncocyte
  • Quest Diagnostics

Group 3: Emerging and niche players

  • Uromonitor

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the bladder cancer array market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 9.0% is calculated from the resulting values.

The market is divided by test, by use, by buyer, by array format, by clinical question. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the bladder cancer array market?

The global bladder cancer array market is estimated at USD 280 mn in 2025 and USD 308 mn in 2026.

How fast will the bladder cancer array market grow?

It is forecast to reach USD 729 mn by 2036, a compound annual growth rate of 9.0% from 2026, an increase of USD 421 mn.

Which country is the largest market for bladder cancer array?

United States is the largest market by revenue at USD 142 mn in 2026, 46.0% of the global total. The three largest countries together hold 61.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 11.8% a year from 2026 to 2036.

Which bladder cancer array segment is largest?

In the by test split, Methylation and mutation assays is the largest segment with 34.0% of 2026 revenue.

Who are the leading bladder cancer array companies?

Global leaders include Abbott, Pacific Edge, Qiagen, Exact Sciences.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Birch Allergy Treatment Blister Machine →

All Healthcare markets →

Request a sample